Skip to main content
BMC Cancer logoLink to BMC Cancer
. 2020 Aug 7;20:736. doi: 10.1186/s12885-020-07246-w

Correction to: Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas

Congxiao Wang 1, Shifeng Liu 1, Lijing Peng 2, Kaixian Zhang 3, Wei Li 1, Hao Zhang 1, Ying Luan 4, Peishun Li 3, Xiaokun Hu 1,
PMCID: PMC7412639  PMID: 32767991

Correction to: BMC Cancer 20, 591 (2020)

https://doi.org/10.1186/s12885-020-07086-8

Following publication of the original article [1], the authors identified an error in Fig. 2. The corrected Fig. 2 is given below.

Fig. 2.

Fig. 2

Kaplan-Meier analysis of OS and PFS a The median OS was 22 months in the SI group compared with 21 months in the SRCI group (p = 0.751). b The median PFS was 8 months in the SI group compared with 7 months in the SRCI group (p = 0.203)

Reference

  • 1.Wang C, Liu S, Peng L, et al. Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas. BMC Cancer. 2020;20:591. doi: 10.1186/s12885-020-07086-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES